Drug selection
Although three different CGRP MoAbs are approved in Europe since 2018:
erenumab, galcanezumab and fremanezumab, erenumab and galcanezumab were
the two first funded CGRP MoAbs for migraine prevention in our hospital
back in late 2019, therefore these were the selected ones for the
present study. Erenumab 140 mg was administered every 4 weeks and
galcanezumab 120 mg once monthly. For galcanezumab an initial dose of
240 mg during the first month was required. CGRP MoAbs were administered
via subcutaneous injection.